The cytokine storm of COVID-19: a spotlight on prevention and protection

References

• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Kok K-H, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan [Internet]. Emerg Microbes Infect. 2020;9:221–236; [cited 2020 May 16]. Available from https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1719902
   PubMed Web of Science ®Google Scholar
• Source: ICNARC case mix programme database; 2020.
   Google Scholar
• Zhou F, Yu T, Du R, et al. Articles Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [Internet]. Lancet. 2020;395:1054–1062.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020:1033–1034. DOI:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Hay KA, La¨ıla-A¨ıcha L, Hanafi A, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy Key Points. 2017; [cited 2020 May 12]. Available from: https://ashpublications.org/blood/article-pdf/130/21/2295/1403588/blood793141.pdf
   Google Scholar
• Kim YK, Shin JS, Nahm MH. NOD-like receptors in infection, immunity, and diseases. Yonsei Med J. Yonsei University College of Medicine.2016:5–14. DOI:10.3349/ymj.2016.57.1.5
   PubMed Web of Science ®Google Scholar
• Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages [Internet]. Nat Rev Immunol; [cited 2020 May 17]. Available from: www.nature.com/nri
   Google Scholar
• Ni G, Ma Z, Damania B. cGAS and STING: at the intersection of DNA and RNA virus-sensing networks [Internet]. PLOS Pathog. 2018;14:e1007148; [cited 2020 May 16]. Available from: https://dx.plos.10.1371/journal.ppat.1007148
   PubMed Web of Science ®Google Scholar
• Bezbradica JS, Joyce S. NKT cells join the two step for inflammasome-independent IL-1β release. Cell Rep. 2020;31:107481.
   PubMed Web of Science ®Google Scholar
• Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol Nat Res. 2020:271–272. DOI:10.1038/s41577-020-0312-7.
   PubMed Web of Science ®Google Scholar
• Kumar P, Saini S, Khan S, et al. Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells. Cell Immunol. 2019;339:41–49.
   PubMed Web of Science ®Google Scholar
• Lin S, Wu H, Wang C, et al. Regulatory T cells and acute lung injury: cytokines, uncontrolled inflammation, and therapeutic implications. Front Immunol Frontiers Media S A; 2018. p. 1545. DOI:10.3389/fimmu.2018.01545
   Google Scholar
• Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm”. In: COVID-19.’ J. Infect. W.B. Saunders Ltd; 2020;80(6):607–613
   Google Scholar
• Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions [Internet]. Autoimmun Rev 2020;19:102567; [cited 2020 May 17]. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/32376392
   PubMed Web of Science ®Google Scholar
• Mcgonagle D, Sharif K, O’regan A, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. 2020; [cited 2020 May 17]. Available from: www.elsevier.com/locate/autrev
   Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Cite this article as. Cold Spring [Internet]. Harb Perspect Biol. 2014;6:16295–16296; [cited 2020 May 17]. Available from: www.cshperspectives.org
   PubMed Web of Science ®Google Scholar
• Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55:105954.
   PubMed Web of Science ®Google Scholar
• Mahmud-Al-Rafat A, Majumder A, Rahman KMT, et al. Decoding the enigma of antiviral crisis: does one target molecule regulate all? 2018; [cited 2020 May 17]. Available from: www.elsevier.com/locate/cytokine
   Google Scholar
• Falasca L, Agrati C, Petrosillo N, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22(8):1250–1259
   Google Scholar
• Yang ML, Wang CT, Yang SJ, et al. IL-6 ameliorates acute lung injury in influenza virus infection. Sci Rep. 2017;7:43829
   Web of Science ®Google Scholar
• Wang W, Ye L, Ye L, et al. Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway. Virus Res. 2007;128:1–8.
   PubMed Web of Science ®Google Scholar
• Lai WY, Wang JW, Huang BT, et al. A novel TNF-α-targeting aptamer for TNF-α-mediated acute lung injury and acute liver failure. Theranostics. 2019;9:1741–1751.
   PubMed Web of Science ®Google Scholar
• Perricone C, Triggianese P, Bartoloni E, et al. The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19. 2020; [cited 2020 May 18]; Available from: www.elsevier.com/locate/jautimm
   Google Scholar
• Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130:2202–2205.
   PubMed Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interf Cytokine Res. 2009;29:313–325.
   PubMed Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. 2020; [cited 2020 May 17]; Available from: https://doi.org/
   Google Scholar
• Hwang DM, Chamberlain DW, Poutanen SM, et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18:1–10.
   PubMed Web of Science ®Google Scholar
• Stefanini GG, Montorfano M, Trabattoni D, et al. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes [Internet]. Circulation. 2020 [cited 2020 May 18]. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047525
   Web of Science ®Google Scholar
• Chieffo A, Stefanini GG, Price S, et al. EAPCI position statement on invasive management of acute coronary syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction [Internet]. Eur Heart J. 2020;41:1839–1851; [cited 2020 May 18]. Available from: https://academic.oup.com/eurheartj/article-abstract/41/19/1839/5836093. .
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. [cited 2020 May 18]. Available from: https://www.arcgis.com/apps/opsdash
   Google Scholar
• Bean DM, Kraljevic Z, Searle T, et al. ACE-inhibitors and Angiotensin-2 receptor blockers are not associated with severe SARS- COVID19 infection in a multi-site UK acute hospital trust. Eur J Heart Fail. DOI:10.1101/2020.04.07.20056788.
   Google Scholar
• Li Y, Sun JF, Cui X, et al. The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies. Crit Care Med. 2011;39:1104–1112.
   PubMed Web of Science ®Google Scholar
• Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med NLM (Medline). 2020;382:e60.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol Nat Immunol. 2011;12: 204–212.
   PubMed Web of Science ®Google Scholar
• Wu F, Liu L, Zhou H. Endothelial cell activation in central nervous system inflammation. J Leukoc Biol. 2017;101:1119–1132.
   PubMed Web of Science ®Google Scholar
• Lavi E, Cong L, Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection [Internet]. Exp Mol Pathol 2020;115:104474. [cited 2020 Jun 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32454103
   PubMed Web of Science ®Google Scholar
• Li Y, Fu L, Gonzales DM, et al. Coronavirus neurovirulence correlates with the ability of the virus to induce proinflammatory cytokine signals from astrocytes and microglia. J Virol. 2004;78:3398–3406.
   PubMed Web of Science ®Google Scholar
• Danzi GB, Loffi M, Galeazzi G, et al. Acute pulmonary embolism and COVID-19 pneumonia: a random association?
   Google Scholar
• Bertoletti L, Couturaud F, Montani D, et al. Venous thromboembolism and Covid-19. Med Res. 2020;78:100759.
   Google Scholar
• Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020. DOI:10.1161/CIRCULATIONAHA.120.047430
   PubMed Web of Science ®Google Scholar
• Allen KS. Anticoagulant modulation of inflammation in severe sepsis. World J Crit Care Med. 2015;4:105.
   PubMedGoogle Scholar
• Lemke G, Silverman GJ. Blood clots and TAM receptor signalling in COVID-19 pathogenesis [Internet]. Nat Rev Immunol. 2020;1. [cited 2020 Jun 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32488201
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report [Internet]. N Engl J Med. 2020. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32445440
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review [published online ahead of print, 2020 Apr 13]. JAMA. 2020;10.1001/jama.2020.6019
   Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. J Am Med Assoc. 2020. DOI:10.1001/jama.2020.8630
   Web of Science ®Google Scholar
• Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77:1865–1879.
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience [Internet]. J Med Virol 2020;92:814–818;[cited 2020 May 20]. Available from: http://doi.wiley.com/10.1002/jmv.25801
   PubMed Web of Science ®Google Scholar
• de Toni L, Garolla A, Di Nisio A, et al. Caution in the management of SARS-CoV-2 infection in males [published online ahead of print, 2020 May 26]. Andrology. 2020;10.1111
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(271–280.e8). DOI:10.1016/j.cell.2020.02.052
   Web of Science ®Google Scholar
• Liaudet L, Szabo C. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease [Internet]. Crit Care. 2020;24:318. [cited 2020 Jun 9]. Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03055-6
   PubMed Web of Science ®Google Scholar
• Feng CG, Karupiah G, Levy DE, et al. Ponatinib protects mice from lethal influenza infection by suppressing cytokine storm. Front Immunol. 2019;1:1393. [cited 2020 May 14]. Available from: www.frontiersin.org
   Google Scholar
• Brun-Buisson C, Richard JCM, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183:1200–1206.
   PubMed Web of Science ®Google Scholar
• Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398–400.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Li R, Liu S. Immunoregulation with mTOR inhibitors to prevent COVID‐19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines [Internet]. J Med Virol. 2020;jmv.26009; [cited 2020 May 18]. Available from:: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26009
   Web of Science ®Google Scholar
• Wang C-H, Chung F-T, Lin S-M, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure [Internet]. Crit Care Med 2014;42:313–321; [cited 2020 May 18]. Available from: http://journals.lww.com/00003246-201402000-00010
   PubMed Web of Science ®Google Scholar
• Ronco C, Navalesi P, Vincent JL. Coronavirus epidemic: preparing for extracorporeal organ support in intensive care. Lancet Respir Med. 2020;8:240–241.
   PubMed Web of Science ®Google Scholar
• Kazory A, Ronco C, McCullough PA. SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill. Proc (Bayl Univ Med Cent). 2020;0(0):1–6
   Google Scholar
• Joseph B, Khalil M, Hashmi A, et al. Survival benefits of remote ischemic conditioning in sepsis. J Surg Res. 2017;213:131–137.
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Yellon DM Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol. 2016;13(4):193–209
   Google Scholar
• Hausenloy DJ, Kharbanda RK, Møller UK, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet. 2019;394:1415–1424.
   PubMed Web of Science ®Google Scholar
• Pickard JMJ, Davidson SM, Hausenloy DJ, et al. Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning.Basic Res Cardiol. 2016;111(4):50
   Google Scholar
• Rossello X, Yellon DM. The RISK pathway and beyond. Basic Res Cardiol. 2017;113(1):2
   Google Scholar
• Bromage DI, Pickard JMJ, Rossello X, et al. Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovasc Res. 2017;113(3):288–297
   Google Scholar
• Heusch G. Critical issues for the translation of cardioprotection. Circ Res. 2017;120:1477–1486.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53(1):31–47
   Google Scholar
• Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12:217–234.
   PubMed Web of Science ®Google Scholar
• Davidson SM, Ferdinandy P, Andreadou I, et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury JACC review topic of the week. J Am Coll Cardiol. 2019;73(1):89–99
   Google Scholar
• Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol Nat Res. 2020;16: 308–310.
   PubMed Web of Science ®Google Scholar
• Lin H, Wang W, Lee M, et al. Current status of septic cardiomyopathy: basic science and clinical progress. Front Pharmacol Front Media. 2020. DOI:10.3389/fphar.2020.00210
   Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008
   PubMed Web of Science ®Google Scholar
• Zhong J, Tan Y, Lu J, et al. Therapeutic contribution of melatonin to the treatment of septic cardiomyopathy: A novel mechanism linking Ripk3-modified mitochondrial performance and endoplasmic reticulum function. Redox Biol. 2019;26:101287
   Google Scholar
• Narumiya S, Thumkeo D. Rho signaling research: history, current status and future directions. FEBS Lett. 2018;592:1763–1776.
   PubMed Web of Science ®Google Scholar
• Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28:296–302.
   PubMed Web of Science ®Google Scholar
• Batchelor TJP, Sadaba JR, Ishola A, et al. Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery. Br J Pharmacol. 2001;132:302–308.
   PubMed Web of Science ®Google Scholar
• Galvão I, Athayde RM, Perez DA, et al. ROCK Inhibition drives resolution of acute inflammation by enhancing neutrophil apoptosis. Cells. 2019;8:964.
   Web of Science ®Google Scholar